The Detox and Cleanse Danger: What Your Kidneys Really Need

In this episode of Wellness Focused, Dr. Bismah Irfan breaks down the exciting new research on Sibiprenly-Mab, a promising monoclonal antibody treatment for IgA Nephropathy (IgAN) presented at Kidney Week 2025.She explains how this medication targets APRIL, a key survival signal for the immune cells that produce the harmful Galactose-deficient IgA (Gd-IgA1). By blocking APRIL, Sibiprenly-Mab reduces the production of these pathogenic antibodies at their source—leading to a 56% reduction in proteinuria and remission in over a third of trial participants.But while the drug shows incredible potential as a disease-modifying therapy, Dr. Bismah highlights what it doesn’t address: the root causes of immune dysregulation that drive IgAN. She discusses overlooked triggers like gut barrier dysfunction, microbiome imbalance, hidden infections, toxins, and food sensitivities—and explains why integrating functional medicine with conventional treatment leads to more durable, long-term healing.If you or a loved one has IgA Nephropathy, this is an essential, hopeful episode that shows how cutting-edge science and root-cause medicine can work together.----Dr. Bismah Irfan breaks down the new IgA Nephropathy drug Sibiprenly-Mab, how it works, its promising clinical results, and why addressing root causes through functional medicine remains essential for long-term kidney healing.----Dr. Bismah Irfan, MDFacebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/KidneyHealthMD⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/kidney.healthmd/⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/drbismah/⁠⁠⁠⁠⁠⁠⁠⁠⁠Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.drbismah.com/about/⁠⁠⁠⁠⁠⁠⁠⁠⁠-----Produced by DrTalks ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drtalks.com/podcast/